BioPharmSignal logoBioPharmSignal

Biotech News

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics (ELVN)Enliven TherapeuticsCompany update

BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in the following

Open original release

Related news

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

NRIXNurix Therapeutics2026-05-13 11:00 EST

Nurix Therapeutics to Participate in Upcoming Investor Conferences

KYMRKymera2026-05-06 11:00 EST

Kymera Therapeutics to Participate in Upcoming May Investor Conferences

ARGXArgenx2026-05-27 05:00 EST

argenx to Present at Upcoming Investor Conferences

GERNGeron2026-05-05 12:00 EST

Geron Plans to Present at Upcoming Investor Conferences

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

EXELExelixis2026-05-27 20:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

SNDXSyndax Pharmaceuticals2026-05-20 11:00 EST

Syndax Announces Participation in Upcoming Investor Conferences

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

View all latest news

Enliven Therapeutics

Enliven Therapeutics is an oncology company focused on targeted therapies and precision cancer medicine. Its development strategy emphasizes genetically defined cancers and differentiated molecules.

Recent company news

ELVNEnliven Therapeutics2026-06-03 20:05 EST

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

ELVNEnliven Therapeutics2026-05-21 20:05 EST

Enliven Therapeutics to Present at Upcoming Investor Conferences

ELVNEnliven Therapeutics2026-05-12 13:53 EST

Enliven Therapeutics Announces Oral Presentation at the EHA 2026 Congress Featuring Additional Positive Phase 1 Clinical Trial Data for ELVN-001 in CML

ELVNEnliven Therapeutics2026-05-07 20:05 EST

Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update

ELVNEnliven Therapeutics2026-03-03 21:05 EST

Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Stock data

Close
52.74 USD
Market cap
2.16B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States